Core Viewpoint - Federal Pharmaceutical (03933) has seen a stock increase of over 3%, currently trading at HKD 13, with a transaction volume of HKD 50.78 million. The company announced that its wholly-owned subsidiary, Federal Biotech (Zhuhai Hengqin) Co., Ltd., has completed Phase II clinical trials for its innovative drug UBT251 in overweight/obese patients in China, showing promising results [1]. Group 1 - The Phase II clinical study of UBT251 (GLP-1/GIP/GCGR) demonstrated impressive weight loss results, outperforming Eli Lilly's retatrutide at a lower dosage over 24 weeks [1]. - The safety profile of UBT251 showed mostly mild to moderate adverse effects, primarily gastrointestinal reactions [1]. - Huatai Securities expressed optimism regarding the strong Phase II data from China, suggesting that the recent initiation of global Phase II trials by Novo Nordisk may enhance the certainty of UBT251's overseas sales potential [1].
联邦制药涨超3% UBT251国内II期减重数据整体表现惊艳 机构看好其海外销售空间